Adult nephron-specific MR-deficient mice develop a severe renal PHA-1 phenotype.
Lausanne, Switzerland. In Pflugers Arch, Feb 2016
Germline loss-of-function mutations of the mineralocorticoid receptor (MR) in humans and in mice lead to the "renal" form of type 1 pseudohypoaldosteronism (PHA-1), a case of aldosterone resistance characterized by salt wasting, dehydration, failure to thrive, hyperkalemia, and metabolic acidosis.
Aldosterone alters the chromatin structure of the murine endothelin-1 gene.
Gainesville, United States. In Life Sci, Feb 2016
SIGNIFICANCE: The evidence supports a model in which aldosterone activation of the mineralocorticoid receptor (MR) results in the MR-hormone complex binding at HRE at -671bp to open chromatin structure around other regulatory elements in the Edn1 gene.
Up-Regulation of FGF23 Release by Aldosterone.
Tübingen, Germany. In Biochem Biophys Res Commun, Feb 2016
Aldosterone further increased Fgf23 transcript levels in UMR106 cells, an effect reversed by mineralocorticoid receptor blockers spironolactone and eplerenone, SGK1 inhibitor EMD638683, NFκB-inhibitor withaferin A, and Ca(2+) channel blocker YM58483.
The Glucocorticoid Receptor: Cause or Cure for Obesity?
Toledo, Philippines. In Am J Physiol Endocrinol Metab, Jan 2016
Alternative mechanisms are then proposed for the lipogenic actions of GCs, including induction of GC resistance by the GRβ isoform, and promotion of lipogenesis by GC activation of the mineralocorticoid receptor (MR).
Resistant hypertension: a review of diagnosis and management.
Dallas, United States. In Jama, 2014
An increasing body of evidence has suggested benefits of mineralocorticoid receptor antagonists, such as eplerenone and spironolactone, in improving blood pressure control in patients with resistant hypertension, regardless of circulating aldosterone levels.